Who can pay for innovative medicines?
作者信息
Decramer Stefaan, Decramer Marc
出版信息
Eur Respir J. 2013 Mar;41(3):495-6. doi: 10.1183/09031936.00135412.
PMID:23456929
Abstract
摘要
相似文献
1
Who can pay for innovative medicines?谁能支付创新药物的费用？
Eur Respir J. 2013 Mar;41(3):495-6. doi: 10.1183/09031936.00135412.
2
Will the innovative medicines initiative really deliver innovative medicines?创新药物计划真的能带来创新药物吗？
Mol Oncol. 2008 Oct;2(3):203-5. doi: 10.1016/j.molonc.2008.07.007. Epub 2008 Jul 31.
3
US drug manufacturers set up joint testing group.美国药品制造商成立联合测试小组。
BMJ. 2012 Sep 21;345:e6394. doi: 10.1136/bmj.e6394.
4
The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.药物研发的经济学以及药物疗法在市场中的最终估值。
Clin Pharmacol Ther. 2008 Aug;84(2):263-6. doi: 10.1038/clpt.2008.117. Epub 2008 Jun 11.
5
Foreign free riders and the high price of US medicines.外国搭便车者与美国药品的高昂价格。
BMJ. 2005 Oct 22;331(7522):958-60. doi: 10.1136/bmj.331.7522.958.
6
Drug discovery.药物发现
Science. 2004 Mar 19;303(5665):1729. doi: 10.1126/science.303.5665.1729.
7
[Objectives of rational and economic therapy of internal diseases].[内科疾病合理与经济治疗的目标]
Klin Med (Mosk). 1991 Jun;69(6):103-8.
8
Drug and vaccine development for infectious diseases: the value of priority review vouchers.传染病的药物和疫苗研发：优先审评券的价值
Clin Pharmacol Ther. 2009 Jun;85(6):571-2. doi: 10.1038/clpt.2009.53.
9
Outsourcing lead optimization: the eye of the storm.外包先导优化：风暴之眼。
Drug Discov Today. 2011 Feb;16(3-4):147-57. doi: 10.1016/j.drudis.2010.11.012. Epub 2010 Dec 8.
10
Inadequately met needs.需求未得到充分满足。
Nat Biotechnol. 2011 May;29(5):371. doi: 10.1038/nbt.1880.
Zotero 插件